APEI Stock Analysis: American Public Education | NASDAQ
Education & Training Services | NASDAQ, USA | Market Cap: 761m USD | 12M Return: 34.6% | US02913V1035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.40M
Qual. Beats: 4
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
American Public Education, Inc. (NASDAQ: APEI) is a U.S.-based provider of online and campus-based postsecondary education, operating through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers degree, certificate, and diploma programs across fields such as nursing, national security, military studies, intelligence, homeland security, business, health science, information technology, justice studies, education, and liberal arts, and provides career learning and leadership training to the federal workforce. Its nursing-focused segment delivers pre-licensure nursing education, including practical nursing diplomas, associate degrees in nursing, and a bachelor of science in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.
APEI operates within the for-profit education services sector, an industry that has historically drawn a significant share of its enrollment from military-affiliated students, active-duty service members, veterans, and public sector employees, a demographic that tends to value flexible online learning formats. The companys multi-brand structure, combining a distance-learning university with campus-based institutions, reflects a common consolidation strategy in the postsecondary education market, where operators seek to diversify across delivery models and program mix.
- Nursing demand drives Rasmussen and Hondros enrollment growth
- Military enrollment and DoD tuition policy impact APUS revenue
- 90/10 rule compliance and Title IV regulation risk persists
| Net Income: 45.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 29.28% < 20% (prev 23.59%; Δ 5.69% < -1%) |
| CFO/TA 0.16 > 3% & CFO 85.6m > Net Income 45.7m |
| Net Debt (137.8m) to EBITDA (83.0m): 1.66 < 3 |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.8m) vs 12m ago 4.30% < -2% |
| Gross Margin: 54.61% > 18% (prev 53.39%; Δ 1.22% > 0.5%) |
| Asset Turnover: 124.3% > 50% (prev 119.9%; Δ 4.32% > 0%) |
| Interest Coverage Ratio: 18.60 > 6 (EBIT TTM 66.8m / Interest Expense TTM 3.59m) |
| A: 0.36 (Total Current Assets 282.5m - Total Current Liabilities 87.0m) / Total Assets 537.7m |
| B: 0.01 (Retained Earnings 6.00m / Total Assets 537.7m) |
| C: 0.12 (EBIT TTM 66.8m / Avg Total Assets 537.6m) |
| D: 1.40 (Book Value of Equity 314.1m / Total Liabilities 223.7m) |
| Altman-Z'' = 4.73 = AA |
| DSRI: 0.95 (Receivables 39.6m/40.1m, Revenue 668.0m/644.5m) |
| GMI: 0.98 (GM 53.39% / 54.61%) |
| AQI: 0.93 (AQ_t 0.24 / AQ_t-1 0.26) |
| SGI: 1.04 (Revenue 668.0m / 644.5m) |
| TATA: -0.07 (NI 45.7m - CFO 85.6m) / TA 537.7m) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of November 05, 2026, the stock is trading at USD 42.41 with a total of 260,602 shares traded. Over the past week, the price has changed by -3.66%, over one month by -4.50%, over three months by -20.61% and over the past year by +34.63%.
Current recommended Stop Loss: 38.20 (which is 9.9% or 2.3 ATR below the current price).
American Public Education has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy APEI.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62 | 46.2% |
P/E Trailing = 16.7702
P/E Forward = 13.2979
P/S = 1.1394
P/B = 2.3636
P/EG = 0.8866
Revenue TTM = 668.0m USD
EBIT TTM = 66.8m USD
EBITDA TTM = 83.0m USD
Long Term Debt = 81.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.1m USD (from shortTermDebt, last quarter)
Debt = 214.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 66.2m
Net Debt = 137.8m USD (calculated: Debt 214.0m - CCE 76.3m)
Enterprise Value = 899.0m USD (761.2m + Debt 214.0m - CCE 76.3m)
Interest Coverage Ratio = 18.60 (Ebit TTM 66.8m / Interest Expense TTM 3.59m)
EV/FCF = 12.83x (Enterprise Value 899.0m / FCF TTM 70.1m)
FCF Yield = 7.79% (FCF TTM 70.1m / Enterprise Value 899.0m)
FCF Margin = 10.49% (FCF TTM 70.1m / Revenue TTM 668.0m)
Net Margin = 6.84% (Net Income TTM 45.7m / Revenue TTM 668.0m)
Gross Margin = 54.61% ((Revenue TTM 668.0m - Cost of Revenue TTM 303.2m) / Revenue TTM)
Gross Margin QoQ = 55.37% (prev 54.91%)
Tobins Q-Ratio = 1.67 (Enterprise Value 899.0m / Total Assets 537.7m)
Interest Expense / Debt = 1.68% (Interest Expense 3.59m / Debt 214.0m)
Taxrate = 23.67% (14.2m / 59.8m)
NOPAT = 51.0m (EBIT 66.8m * (1 - 23.67%))
Current Ratio = 3.25 (Total Current Assets 282.5m / Total Current Liabilities 87.0m)
Debt / Equity = 0.68 (Debt 214.0m / totalStockholderEquity, last quarter 314.1m)
Debt / EBITDA = 1.66 (Net Debt 137.8m / EBITDA 83.0m)
Debt / FCF = 1.97 (Net Debt 137.8m / FCF TTM 70.1m)
Total Stockholder Equity = 298.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.50% (Net Income 45.7m / Total Assets 537.7m)
RoE = 15.30% (Net Income TTM 45.7m / Total Stockholder Equity 298.6m)
RoCE = 17.58% (EBIT 66.8m / Capital Employed (Equity 298.6m + L.T.Debt 81.6m))
RoIC = 11.91% (NOPAT 51.0m / Invested Capital 428.5m)
WACC = 4.61% (E(761.2m)/V(975.2m) * Re(5.54%) + D(214.0m)/V(975.2m) * Rd(1.68%) * (1-Tc(0.24)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.71 | Cagr: 2.46%
[DCF] Terminal Value 77.97% ; FCFF base≈62.1m ; Y1≈71.2m ; Y5≈104.8m
[DCF] Fair Price = 78.65 (EV 1.58b - Net Debt 137.8m = Equity 1.44b / Shares 18.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.00 | # QB: 4
Revenue Correlation: 98.42 | Revenue CAGR: 4.30% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.36 | Chg30d=+0.00% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=3.02 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+37.9% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=3.76 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+24.3% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -22% (up=2, down=4)